Gastric carcinoma (GC) is the fourth leading cause of cancer-related mortality worldwide. Patients with advanced GC tend to have poor prognoses and shortened survival. Finding novel predictive biomarkers for GC prognosis is an urgent need. Mitophagy is the selection degradation of damaged mitochondria to maintain cellular homeostasis, which has been shown to play both pro- and anti-tumor effects. This study combined single-cell sequencing data and transcriptomics to screen mitophagy-related genes (MRGs) associated with GC progression and analyze their clinical values. Reverse transcription-quantitative PCR (RT-qPCR) and immunochemistry (IHC) further verified gene expression profiles. A total of 18 DE-MRGs were identified after taking an intersection of single-cell sequencing data and MRGs. Cells with a higher MRG score were mainly distributed in the epithelial cell cluster. Cell-to-cell communications among epithelial cells with other cell types were significantly upregulated. We established and validated a reliable nomogram model based on DE-MRGs (GABARAPL2 and CDC37) and traditional clinicopathological parameters. GABARAPL2 and CDC37 displayed different immune infiltration states. Given the significant correlation between hub genes and immune checkpoints, targeting MRGs in GC may supplement more benefits to patients who received immunotherapy. In conclusion, GABARAPL2 and CDC37 may be prognostic biomarkers and candidate therapeutic targets of GC.
Introduction: Microsomal triglyceride transfer protein (MTTP) is an essential lipid transfer protein for the synthesis and secretion of very low density lipoprotein (VLDL) in hepatocytes and chylomicrons (CM) in intestinal cells. Further researches have revealed that MTTP exerted its functions in a variety of tissues beyond the liver and intestine, including the heart, neural tissues and antigen-presenting cells. Dysregulation of MTTP expression can lead to many diseases, such as lipid metabolism disorders, insulin resistance and cardiovascular diseases. Despite its importance, research on MTTP in cancer is limited, with no comprehensive pan-cancer studies available.Methods: MTTP expression was explored with the TIMER 2.0 and Sangerbox databases. The pathological stages and survival analysis of MTTP were analyzed via GEPIA and Kaplan Meier plotter. The gene mutations of MTTP were analyzed by cBioPortal database. The immune landscape of MTTP in the tumor microenvironment(TME) was analyzed using the TIMER 2.0 and single-cell sequencing. Based on the RNA-seq data in TCGA, we constructed GSEA enrichment analysis for MTTP. We identified the pro-tumor and anti-ferroptosis functions of MTTP in gastric cancer (GC) cells by in vitro and in vivo experiments, and analyzed the effect of TME on ferroptosis by single-cell sequencing.Results: MTTP expression was elevated in at least 1/3 tumors. High expression of MTTP was associated with poor prognosis in most tumors. MTTP levels were significantly correlated with three scores (immune, stromal, and extimate) and immune checkpoints in at least half of tumor types. Single cell sequencing of immune cells showed that MTTP was mainly expressed in macrophages, especially in microglia. MTTP increased in GC and MTTP knockdown limited the proliferation, migration and invasion abilities of GC cells, accompanied by increased sensitivity to ferroptosis. In addition, analyzing the ferroptosis genes associated with MTTP at the single cell level, we found that macrophages may be involved in the ferroptosis process in GC.Conclusions: Our pan-cancer study emphasizes that MTTP is a promising prognostic and immunotherapeutic biomarker in tumors. High expression of MTTP is correlated with the infiltration of diverse immune cells and regulates ferroptosis in GC cells, providing a potential target for tumor immunotherapy.
Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor durability and severe toxicity (cytokine release syndrome and neurotoxicity) are still huge challenges. Therefore, relapsed/refractory multiple myeloma (RRMM), characterized by the nature of clinicopathologic and molecular heterogeneity, is frequently associated with poor prognosis. B Cell Maturation Antigen (BCMA) is the most successful target for CAR-T therapy, and other potential targets either for single-target or dual-target CAR-T are actively being studied in numerous clinical trials. Moreover, mechanisms driving resistance or relapse after CAR-T therapy remain uncharacterized, which might refer to T-cell clearance, antigen escape, and immunosuppressive tumor microenvironment. Engineering CAR T-cell to improve both efficacy and safety continues to be a promising area for investigation. In this review, we aim to describe novel tumor-associated neoantigens for MM, summarize the data from current MM CAR-T clinical trials, introduce the mechanism of disease resistance/relapse after CAR-T infusion, highlight innovations capable of enhanced efficacy and reduced toxicity, and provide potential directions to optimize manufacturing processes.
Gastric cancer (GC) is one of the most frequently diagnosed types of cancer worldwide, and exploring its potential therapeutic targets is particularly important for improving the prognosis of patients with GC. The aim of the present study was to investigate the association between serine/threonine kinase 17a (STK17A) expression and GC prognosis. STK17A expression was measured by quantitative real‑time PCR, western blotting and immunohistochemical staining. Standard stable transfection technology was also used to construct overexpression and knockdown cell lines. Wound healing, Transwell, Cell Counting Kit‑8 and colony formation assays, as well as other methods, were used to explore the function and underlying molecular mechanism of STK17A in GC. The results indicated that STK17A overexpression significantly promoted the proliferation and migration of GC cells. The clinical significance of STK17A in a cohort of 102 cases of GC was assessed by clinical correlation and Kaplan‑Meier analyses. Overexpression of STK17A was demonstrated to be associated with tumor invasion depth (P<0.001), lymph node metastasis (P<0.001) and poor prognosis in terms of 5‑year survival (P<0.001). In addition, Cox multivariate analysis revealed that STK17A expression was an independent risk factor for overall and progress‑free survival (P<0.001). Therefore, STK17A may be a valuable biomarker for the prognosis of patients with GC.
Background: Gastric cancer (GC) ranks fifth for morbidity and third for mortality worldwide. The N6-methyladenosine (m6A) mRNA methylation is crucial in cancer biology and progression. However, the relationship between m6A methylation and gastric tumor microenvironment (TME) remains to be elucidated. Methods: We combined single-cell and bulk transcriptome analyses to explore the roles of m6A-related genes (MRG) in gastric TME. Results: Nine TME cell subtypes were identified from 23 samples. Fibroblasts were further grouped into four subclusters according to different cell markers. M6A-mediated fibroblasts may guide extensive intracellular communications in the gastric TME. The m6A-related genes score (MRGs) was output based on six differentially expressed single-cell m6A-related genes (SCMRDEGs), including GHRL, COL4A1, CAV1, GJA1, TIMP1, and IGFBP3. The protein expression level was assessed by immunohistochemistry. We identified the prognostic value of MRGs and constructed a nomogram model to predict GC patients’ overall survival. MRGs may affect treatment sensitivity in GC patients. Conclusion: Our study visualized the cellular heterogeneity of TME at the single-cell level, revealed the association between m6A mRNA modification and intracellular communication, clarified MRGs as an independent risk factor of prognosis, and provided a reference for follow-up treatment.